Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results

XVII International Drug Resistance Workshop June 10-14, 2008 XVII International AIDS Conference August 3-8, 2008 BMO Capital Markets Focus on Healthcare Conference August 5-6, 2008   XVII International Drug Resistance Workshop Materials